EU Industry Welcomes New Schengen Strategy’s Green Lanes

7 April 2021

New report assesses progress on biosimilar medicine policies across Europe

29 March 2021

Biosimilar medicines are increasingly relevant to public health as emphasised by the […]

EU industrial policy can dramatically improve medicines manufacturing resilience and security of supply

17 March 2021

New report reveals need for pricing and reimbursement and procurement reforms to ensure patient access and healthcare sustainability

1 March 2021

Smart policies will encourage more critical medicines manufacturing in Europe

26 February 2021

EU must address barriers to continuous off-patent innovation and grasp opportunity for patients and healthcare

23 February 2021

EU Pharma strategy provides unique moment to establish a regulatory […]

A new medicines trade and health security agenda for the European Commission

19 February 2021

In response to the European Commission Trade Communication published on […]

No further excuse to delay digital regulatory infrastructure for medicines after Covid-19 pandemic

19 February 2021

Smarter use of generic, biosimilar and value added medicines will ensure equitable access to cancer care

4 February 2021

AESGP, EFPIA and Medicines for Europe reflections on the European Medicines Agency, the Heads of Medicines Agencies and the European Commission “Key principles for the use of electronic product information for EU medicines” press release.

3 February 2021